ArticleCardiovascular diabetology2026
Fatty liver index-defined hepatic steatosis and impaired fasting glucose differentially associate with incident diabetes and cardiovascular events in older adults: a nationwide cohort study.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHepatic steatosis and prediabetes are increasingly prevalent among older adults; however, their respective impacts on cardiometabolic outcomes remain unclear. We aimed to evaluate the associations of hepatic steatosis and prediabetes with incident diabetes and cardiovascular outcomes in this population.
methodsThis nationwide cohort study included 142,518 adults aged ≥ 65 years without diabetes. Hepatic steatosis was defined using the fatty liver index (FLI ≥ 60), and impaired fasting glucose (IFG) was defined by fasting glucose levels of 100-125 mg/dL. Outcomes included incident diabetes and composite major adverse cardiovascular events (MACE), comprising myocardial infarction, stroke, heart failure, or cardiovascular death, which were analyzed using multivariable Cox proportional hazards models and Fine-Gray subdistribution hazard models.
resultsAt baseline, FLI-defined hepatic steatosis was identified in 6.6% of participants, while 30.6% had IFG. After multivariable adjustment, FLI-defined hepatic steatosis was associated with incident diabetes (SHR 1.67; 95% CI 1.59-1.76; P < 0.001) and composite MACE (SHR 1.21; 95% CI 1.15-1.29; P < 0.001). IFG was associated with an increased risk of incident diabetes (SHR 2.54; 95% CI 2.47-2.62; P < 0.001) but was not independently associated with composite MACE. In joint analyses, FLI-defined hepatic steatosis was consistently associated with an elevated risk of composite MACE regardless of glycemic status, with SHRs of 1.23 (95% CI 1.14-1.32; P < 0.001) among normoglycemic individuals and 1.20 (95% CI 1.11-1.31; P < 0.001) among those with IFG. In contrast, IFG without FLI-defined hepatic steatosis was not associated with an increased risk of composite MACE compared with normoglycemic individuals without FLI-defined hepatic steatosis.
conclusionIn older adults, FLI-defined hepatic steatosis is a strong predictor of both incident diabetes and cardiovascular events, whereas IFG shows no independent association with cardiovascular outcomes.
trial registrationNot applicable (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.